Here are the 424B prospectus supplements from Clinuvel Pharms (CLVLF) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CLVLF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLVLF filings page.
Clinuvel Pharmaceuticals Limited and The Bank of New York Mellon outline the terms governing Clinuvel’s American Depositary Shares, each representing one ordinary share of the Australian company. The revised receipt form reflects that Clinuvel is now subject to periodic reporting under the U.S. Securities Exchange Act of 1934, giving ADS holders access to the company’s SEC-filed reports via EDGAR. The document describes how ADSs are issued, transferred, and surrendered in exchange for underlying shares, including the ability to hold ADSs in certificated or uncertificated (book-entry/DRS) form.
The text details fees and charges borne by ADS holders, such as up to $5.00 per 100 ADSs for issuance or surrender, and up to $0.05 per ADS for cash and annual depositary services. It explains dividend conversion from foreign currency into U.S. dollars, tax withholding, voting procedures for underlying shares, treatment of corporate actions (rights issues, tender offers, redemptions, replacements), and circumstances under which the depositary may suspend deposits, withdrawals, or terminate the program. Liability limitations, amendment and termination mechanics, DTC’s Direct Registration and Profile systems, New York jurisdiction, and jury trial and sovereign immunity waivers are also set out for ADS owners.